Compile Data Set for Download or QSAR
maximum 50k data

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB (change energy unit to kcal/mol)

Found 25 hits in this display   

TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataKi:  0.510nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  56.9nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  56.9nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  72.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  72.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  78.5nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  78.5nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  85.3nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  85.3nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  93.2nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  93.2nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  110nMAssay Description:Inhibition of TYK2 in human PBMC assessed as inhibition of IL-12-stimulated phosphorylation of STAT4 measured by immunoblotting methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetJAK3/JAK1(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  240nMAssay Description:Inhibition of Jak1/Jak3 in human PBMC assessed as inhibition of IL2-stimulated phosphorylation of STAT5More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50:  3.90E+3nMAssay Description:Inhibition of Jak2 in human PBMC assessed as inhibition of GM-CSF-stimulated phosphorylation of STAT5More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of hERG measured by patchclamp assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C8(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A5(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP3A5 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2A6(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2A6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2B6(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2B6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2E1(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2E1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 1A2(Homo sapiens (Human))
Nimbus Therapeutics

Curated by ChEMBL
LigandPNGBDBM406663(US10336752, Compound 1 | US10336752, Compound 2 | ...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed